Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;28(6):e85.
doi: 10.3802/jgo.2017.28.e85.

Survival of gynecological cancers in Turkey: where are we at?

Murat Gultekin  1 , Selin Dundar  2 , Irem Kucukyildiz  2 , Mujdegul Zayifoglu Karaca  2 , Guledal Boztas  2 , Semra Hatice Turan  2 , Ezgi Hacikamiloglu  2 , Bekir Keskinkilic  2
Affiliations

Survival of gynecological cancers in Turkey: where are we at?

Murat Gultekin et al. J Gynecol Oncol. 2017 Nov.

Abstract

Objective: To investigate the 5-year relative survival rates in gynecological cancers diagnosed and treated in Turkey by year 2009 and to compare the results with developed countries.

Methods: Data of patients diagnosed for ovarian, corpus uteri or cervix uteri cancer at year 2009 are collected from 9 national cancer registry centers. Date of deaths are retracted from governmental Identity Information Sharing System (KPS). In order to calculate relative survival rates, national general population mortality tables are obtained from Turkish Statistical Institute (TurkStat). Hakulinen method is used for computing curves by R program. Data for European, Asian and some developed countries were obtained from official web pages.

Results: A total of 1,553 patients are evaluated. Among these, 713 (45.9%) are corpus uteri cancers, while remaining 489 (31.5%) are ovarian and 351 (22.6%) are cervix uteri. Five-year overall relative survival rates are 85%, 50%, and 62% for corpus uteri, ovarian, and cervix uteri, respectively. These figures are between 73%-87% for corpus uteri, 31%-62% for ovarian and 61%-80% for cervix uteri in developed countries. Stage is the most important factor for survival in all cancers. Five-year relative survival rates in corpus uteri cancers are 92%, 66%, and 38% for localized, regional, and distant metastatic disease, respectively. These figures are 77%, 57%, and 29% for ovarian; 80%, 50%, and 22% for cervix uteri.

Conclusion: This is the first report from Turkey giving national overall relative survival for gynecological cancers from a population based cancer registry system.

Keywords: Cervix Uteri; Corpus Uteri Cancers; Gynecologic Neoplasms; Ovarian Diseases; Relative Survival; Turkey.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Five-year relative survival curves. SEER, Surveillance, Epidemiology, and End Results.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0 (IARC CancerBase No. 11) [Internet] Lyon: International Agency for Research on Cancer; 2013. [cited 2017 Apr 10]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
    1. Stewart SL, Lakhani N, Brown PM, Larkin OA, Moore AR, Hayes NS. Gynecologic cancer prevention and control in the National Comprehensive Cancer Control Program: progress, current activities, and future directions. J Womens Health (Larchmt) 2013;22:651–657. - PMC - PubMed
    1. Akdag R, Tosun N, Cinal A. Türkiye'de özellikli planlama gerektiren sağlık hizmetleri 2011??023 [Internet] Ankara: Sağlık Bakanlığı Tedavi Hizmetleri Genel Müdürlüğü; 2011. [cited 2017 Apr 10]. Available from: http://planlamadb.saglik.gov.tr/Eklenti/3167,turkiyede-ozellikli-planlam....
    1. Parkin DM, Hakulinen T. Analysis of survival. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer; 1991. pp. 159–176.
    1. Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed. 2006;81:272–278. - PubMed

MeSH terms